These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7420350)

  • 1. Stereochemical requirements for cannabinoid activity.
    Mechoulam R; Lander N; Varkony TH; Kimmel I; Becker O; Ben-Zvi Z; Edery H; Porath G
    J Med Chem; 1980 Oct; 23(10):1068-72. PubMed ID: 7420350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationships defining the ACD-tricyclic cannabinoids: cannabinoid receptor binding and analgesic activity.
    Melvin LS; Milne GM; Johnson MR; Wilken GH; Howlett AC
    Drug Des Discov; 1995 Nov; 13(2):155-66. PubMed ID: 8872458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereochemical requirements for cannabimimetic activity.
    Mechoulam R; Lander N; Srebnik M; Breuer A; Segal M; Feigenbaum JJ; Jarbe TU; Consroe P
    NIDA Res Monogr; 1987; 79():15-30. PubMed ID: 3125475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular determinants of cannabinoid activity: toward the design of cannabinoid analgesics with reduced psychoactive liability.
    Reggio PH
    NIDA Res Monogr; 1993; 134():210-28. PubMed ID: 8289879
    [No Abstract]   [Full Text] [Related]  

  • 5. The importance of the orientation of the C9 substituent to cannabinoid activity.
    Reggio PH; Greer KV; Cox SM
    J Med Chem; 1989 Jul; 32(7):1630-5. PubMed ID: 2738895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential physiological and behavioral cues observed in individuals smoking botanical marijuana versus synthetic cannabinoid drugs.
    Chase PB; Hawkins J; Mosier J; Jimenez E; Boesen K; Logan BK; Walter FG
    Clin Toxicol (Phila); 2016; 54(1):14-9. PubMed ID: 26653952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective and potent analgetics derived from cannabinoids.
    Johnson MR; Melvin LS; Althuis TH; Bindra JS; Harbert CA; Milne GM; Weissman A
    J Clin Pharmacol; 1981; 21(S1):271S-282S. PubMed ID: 6271833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of novel aminocannabinoids in baboons.
    Edery H; Porath G; Mechoulam R; Lander N; Srebnik M; Lewis N
    J Med Chem; 1984 Oct; 27(10):1370-3. PubMed ID: 6541257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of a potential rabbit model for structure--behavioral activity studies of cannabinoids.
    Consroe P; Martin AR; Fish BS
    J Med Chem; 1982 May; 25(5):596-9. PubMed ID: 7086846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discriminative stimulus effects of the cannabinoid antagonist, SR 141716A, in delta -sup-9-tetrahydrocannabinol-treated rhesus monkeys.
    McMahon LR; France CP
    Exp Clin Psychopharmacol; 2003 Nov; 11(4):286-93. PubMed ID: 14599262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabimimetic activity of novel enantiomeric, benzofuran cannabinoids.
    Mechoulam R; Breuer A; Järbe TU; Hiltunen AJ; Glaser R
    J Med Chem; 1990 Mar; 33(3):1037-43. PubMed ID: 2155318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of the role of the phenolic hydroxyl in cannabinoid activity.
    Reggio PH; Seltzman HH; Compton DR; Prescott WR; Martin BR
    Mol Pharmacol; 1990 Dec; 38(6):854-62. PubMed ID: 2174506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enantiomeric cannabinoids: stereospecificity of psychotropic activity.
    Mechoulam R; Feigenbaum JJ; Lander N; Segal M; Järbe TU; Hiltunen AJ; Consroe P
    Experientia; 1988 Sep; 44(9):762-4. PubMed ID: 3416993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rational search for the separation of psychoactivity and analgesia in cannabinoids.
    Reggio PH; McGaughey GB; Odear DF; Seltzman HH; Compton DR; Martin BR
    Pharmacol Biochem Behav; 1991 Nov; 40(3):479-86. PubMed ID: 1806940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, Psychotic Onset.
    Martinotti G; Santacroce R; Papanti D; Elgharably Y; Prilutskaya M; Corazza O
    CNS Neurol Disord Drug Targets; 2017; 16(5):567-575. PubMed ID: 28412921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells.
    Puffenbarger RA; Boothe AC; Cabral GA
    Glia; 2000 Jan; 29(1):58-69. PubMed ID: 10594923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic cannabinoids: the hidden side of Spice drugs.
    Pintori N; Loi B; Mereu M
    Behav Pharmacol; 2017 Sep; 28(6):409-419. PubMed ID: 28692429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural modifications of the cannabinoid side chain towards C3-aryl and 1',1'-cycloalkyl-1'-cyano cannabinoids.
    Papahatjis DP; Nahmias VR; Andreou T; Fan P; Makriyannis A
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1616-20. PubMed ID: 16387492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1'-substituted delta 8-tetrahydrocannabinols.
    Papahatjis DP; Kourouli T; Abadji V; Goutopoulos A; Makriyannis A
    J Med Chem; 1998 Mar; 41(7):1195-200. PubMed ID: 9544219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral Determinants of Cannabinoid Self-Administration in Old World Monkeys.
    John WS; Martin TJ; Nader MA
    Neuropsychopharmacology; 2017 Jun; 42(7):1522-1530. PubMed ID: 28059083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.